Health Care·Biotechnology·$185.7B
Amgen Inc. (AMGN) is a leading biotechnology company focused on developing innovative therapies for serious illnesses....
Earnings Per Share (EPS)
EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.
Revenue
Revenue figures will provide insight into Amgen's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+9.81%
Avg Stock Reaction
-0.41%
In Q4 2025, Amgen reported an EPS of $5.29, exceeding expectations by 11.18%. However, the stock experienced a slight decline the following day.
Management Promises & Guidance
Analysts are generally optimistic about Amgen's upcoming earnings, expecting solid EPS and revenue figures.
Bull Case
If Amgen meets or exceeds the consensus estimates, it could signal strong demand for its products and effective cost management.
Bear Case
A miss on earnings or revenue could raise concerns about the company's growth prospects and market competition.
Earnings Per Share (EPS)
$4.76EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.
Revenue
$8.6BRevenue figures will provide insight into Amgen's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Amgen's EPS exceed the consensus estimate of $4.76?
A strong EPS could reinforce confidence in Amgen's profitability and operational efficiency.
Q2
How does the revenue of $8.6B compare to previous quarters?
Revenue growth is critical for assessing the company's market position and demand for its products.
Why consensus could be wrong
The consensus may underestimate Amgen's ability to leverage its product pipeline for growth, especially in emerging markets.
Supporting Evidence
Amgen has consistently beaten EPS estimates, indicating strong management performance.
Options pricing suggests a larger move than historical averages, indicating potential for a surprise.
Recent product launches have shown promising early sales figures.
Key Risk
If Amgen's revenue exceeds $9B, it could challenge the current market narrative of slowing growth.
Pre-commit to what would confirm each case.
The market is debating Amgen's ability to sustain growth amid competitive pressures and changing healthcare dynamics.
Bull Confirmed If
An EPS of $4.85 or higher would confirm strong operational performance.
Bear Confirmed If
An EPS below $4.50 would raise concerns about profitability and market competitiveness.
Implied Move
±6.63%
Historical Avg
±0.8%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.
Options are pricing ±3.0% while AMGN has averaged ±0.8% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Amgen beats expectations, history suggests a potential stock increase of around 0.84%, confirming strong demand and operational efficiency.
In-Line / Cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
A miss on earnings could lead to a decline in stock price, with historical data suggesting a potential drop of around 0.41%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026